Biophore to acquire FDA-approved sterile injectable facility in Indore

The transaction is expected to close in Q4 2026, subject to applicable Indian regulatory requirements and customary closing conditions

Biophore has entered into a definitive agreement with Par Health to acquire an FDA-approved sterile injectable manufacturing facility in Indore, India, in a strategic move to expand its global finished-dose manufacturing capabilities.

The transaction is expected to close in Q4 2026, subject to applicable Indian regulatory requirements and customary closing conditions.

The export-oriented facility, located in a Special Economic Zone, offers sterile fill-finish capabilities, bulk formulation, automated filling lines and commercial-scale packaging infrastructure. The acquisition will strengthen Biophore’s ability to cater to growing global demand for complex generic and proprietary injectable products across regulated markets.

The facility will complement Biophore’s existing non-parenteral manufacturing network and expand its capabilities in parenteral manufacturing, enabling the company to better leverage its portfolio of parenteral APIs and provide integrated solutions to customers and partners.

Biophore also plans to retain the facility’s experienced workforce and integrate its expertise with the company’s existing quality systems and operational capabilities. 

Dr. Manik Reddy Pullagurla, Co-Founder & CSO, Biophore, said, “This acquisition represents a meaningful milestone in Biophore’s long-term growth strategy. The Indore facility adds specialized sterile injectable capabilities to our global manufacturing network and strengthens our ability to serve the increasing demand for complex injectable products.”